Global investment platform OurCrowd has launched the $50m Medtech Fund, which will focus exclusively on investing in disruptive medical technologies and therapeutics with the potential to transform global healthcare delivery and patient outcomes.
The OurCrowd community features about 30,000 accredited investors from more than 150 countries. OurCrowd has raised $1bn and invested in 170 portfolio companies and funds.
The Medtech Fund is claimed to be OurCrowd’s first fund dedicated to the medtech market, which is valued globally at $433.7bn in 2018 and estimated to be worth nearly $594.5bn by 2024.
The Medtech Fund will focus on medical devices, therapeutics, medical robotics and new developments in the medical industry.
OurCrowd founder and CEO Jon Medved said: “The creation of the OurCrowd Medtech Fund is a natural extension of the prolific investments we’ve been making in the medtech sector over the past few years. This move will give investors even more accessibility to promising Israeli startups upending the way we live and saving lives.”
Since 2013, the medtech team at the firm claims to have identified, scaled and financed more than $78m across 20 medical technologies. The venture investor says that its new fund is uniquely positioned to tap into both Israeli and global innovation to develop medical solutions in markets where there are clear, unmet clinical needs.
Some of the OurCrowd medtech investments to date include AlphaTau Medical, a radio therapy for solid cancer tumors, UPnRIDE, an electric wheelchair with stable standing and mobility for handicapped individuals, Insightec, an MR-guided ultrasound for non-invasive surgery, MeMed that prevents the misuse of antibiotic.
Other investments include Zebra Medical Vision, a medical imaging insights platform with algorithm-based assistance for radiologists, Sight Diagnostics, a point of care blood diagnostics that uses computer vision, Memic, a robotic arm that improves surgeon’s natural movements and Syqe Medical, a selective-dose pharmaceutical grade medicinal plants inhaler.
OurCrowd Medtech Fund managing partner Morris Laster said: “With rising healthcare costs and an increased focus on outcomes and value, now is the time to introduce disruptive technologies to the marketplace that question the status quo and advance healthcare delivery. The only way to innovate in today’s healthcare environment is to support the companies that are bold enough to truly change the way healthcare is delivered.”